{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:26:02Z","timestamp":1790961962985,"version":"4.1.0"},"reference-count":114,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T00:00:00Z","timestamp":1596672000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2020.01290","type":"journal-article","created":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T10:33:07Z","timestamp":1597314787000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":337,"title":["Mechanisms of Cancer Resistance to Immunotherapy"],"prefix":"10.3389","volume":"10","author":[{"given":"Rilan","family":"Bai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naifei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nawen","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huimin","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiuwei","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,8,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1007\/s00262-016-1895-5","article-title":"The growing world of CAR T cell trials: a systematic review","volume":"65","author":"Holzinger","year":"","journal-title":"Cancer Immunol Immunother"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.3390\/ijms19051340","article-title":"Mechanisms of intrinsic tumor resistance to immunotherapy","volume":"19","author":"Rieth","year":"2018","journal-title":"Int J Mol Sci."},{"key":"B3","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"B4","doi-asserted-by":"publisher","first-page":"4242","DOI":"10.1158\/1078-0432.CCR-16-3133","article-title":"Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate","volume":"23","author":"Kato","year":"2017","journal-title":"Clin Cancer Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1158\/1078-0432.CCR-16-1741","article-title":"Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1\/PD-L1","volume":"23","author":"Champiat","year":"2017","journal-title":"Clin Cancer Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ejca.2017.10.017","article-title":"Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: comparison of RECIST 1.1, irRECIST and iRECIST criteria","volume":"88","author":"Tazdait","year":"2018","journal-title":"Eur J Cancer."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.17.00235","article-title":"Analysis of MDM2 amplification: next-generation sequencing of patients with diverse malignancies","volume":"2","author":"Kato","year":"2018","journal-title":"JCO Precis Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N Engl J Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","article-title":"Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)","volume":"390","author":"Schachter","year":"2017","journal-title":"Lancet."},{"key":"B10","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/imm.12675","article-title":"Antigen processing and immune regulation in the response to tumours","volume":"150","author":"Reeves","year":"2017","journal-title":"Immunology."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/S0960-9822(95)00219-3","article-title":"Antigen-presenting cells. Professionals and amateurs","volume":"5","author":"Sprent","year":"1995","journal-title":"Curr Biol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/nature24473","article-title":"A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy","volume":"551","author":"Luksza","year":"2017","journal-title":"Nature."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1056\/NEJMoa1613493","article-title":"First-line nivolumab in stage IV or recurrent non-small-cell lung cancer","volume":"376","author":"Carbone","year":"2017","journal-title":"N Engl J Med."},{"key":"B14","first-page":"69","article-title":"Neoantigens in cancer immunotherapy","volume-title":"Science","author":"Schumacher","year":"2015"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med."},{"key":"B16","first-page":"409","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume-title":"Science","author":"Le","year":"2017"},{"key":"B17","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/nature12213","article-title":"Mutational heterogeneity in cancer and the search for new cancer-associated genes","volume":"499","author":"Lawrence","year":"2013","journal-title":"Nature."},{"key":"B18","doi-asserted-by":"publisher","first-page":"3223","DOI":"10.1097\/00008390-199706001-00497","article-title":"Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions","volume":"57","author":"de Vries","year":"1997","journal-title":"Cancer Res."},{"key":"B19","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1158\/2159-8290.CD-16-0828","article-title":"Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer","volume":"7","author":"Anagnostou","year":"2017","journal-title":"Cancer Discov."},{"key":"B20","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1586\/1744666X.2014.865519","article-title":"Cellular and molecular mechanisms in cancer immune escape: a comprehensive review","volume":"10","author":"Bhatia","year":"2014","journal-title":"Expert Rev Clin Immunol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/nature10803","article-title":"Expression of tumour-specific antigens underlies cancer immunoediting","volume":"482","author":"DuPage","year":"2012","journal-title":"Nature."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1172\/JCI17656","article-title":"Antigenic drift as a mechanism for tumor evasion of destruction by cytolytic T lymphocytes","volume":"111","author":"Bai","year":"2003","journal-title":"J Clin Invest."},{"key":"B23","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.ccell.2015.10.012","article-title":"Immunological effects of conventional chemotherapy and targeted anticancer agents","volume":"28","author":"Galluzzi","year":"2015","journal-title":"Cancer Cell."},{"key":"B24","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","article-title":"Immunogenic cell death in cancer therapy","volume":"31","author":"Kroemer","year":"2013","journal-title":"Annu Rev Immunol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1158\/0008-5472.CAN-15-1142","article-title":"Calreticulin expression in human non-small cell lung cancers correlates with increased accumulation of antitumor immune cells and favorable prognosis","volume":"76","author":"Fucikova","year":"2016","journal-title":"Cancer Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1080\/15548627.2015.1082022","article-title":"Combined evaluation of LC3B puncta and HMGB1 expression predicts residual risk of relapse after adjuvant chemotherapy in breast cancer","volume":"11","author":"Ladoire","year":"2015","journal-title":"Autophagy."},{"key":"B27","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.cell.2019.08.012","article-title":"Proteomics of melanoma response to immunotherapy reveals mitochondrial dependence","volume":"179","author":"Harel","year":"2019","journal-title":"Cell."},{"key":"B28","doi-asserted-by":"publisher","first-page":"4347","DOI":"10.1158\/0008-5472.CAN-16-0008","article-title":"Melanoma lesions independently acquire T-cell resistance during metastatic latency","volume":"76","author":"Zhao","year":"2016","journal-title":"Cancer Res."},{"key":"B29","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","article-title":"Lag-3, Tim-3, and TIGIT: Co-inhibitory receptors with specialized functions in immune regulation","volume":"44","author":"Anderson","year":"2016","journal-title":"Immunity."},{"key":"B30","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.celrep.2016.03.075","article-title":"Genomic correlates of immune-cell infiltrates in colorectal carcinoma","volume":"15","author":"Giannakis","year":"2016","journal-title":"Cell Rep."},{"key":"B31","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s12967-015-0647-1","article-title":"Loss of tapasin correlates with diminished CD8+ T-cell immunity and prognosis in colorectal cancer","volume":"13","author":"Sokol","year":"2015","journal-title":"J Transl Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"eaah3560","DOI":"10.1126\/scitranslmed.aah3560","article-title":"Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance","volume":"9","author":"Roh","year":"2017","journal-title":"Sci Transl Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"3203","DOI":"10.1158\/1078-0432.CCR-16-1946-T","article-title":"Genomic profiling of patient-derived xenografts for lung cancer identifies B2M inactivation impairing immunorecognition","volume":"23","author":"Pereira","year":"2017","journal-title":"Clin Cancer Res."},{"key":"B34","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1093\/abbs\/gmu041","article-title":"Myeloma cells resistance to NK cell lysis mainly involves an HLA class I-dependent mechanism","volume":"46","author":"Gao","year":"2014","journal-title":"Acta Biochim Biophys Sinica."},{"key":"B35","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.cell.2016.08.069","article-title":"Loss of IFN-\u03b3 pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy","volume":"167","author":"Gao","year":"2016","journal-title":"Cell."},{"key":"B36","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/nri1604","article-title":"Mechanisms of type-I- and type-II-interferon-mediated signalling","volume":"5","author":"Platanias","year":"2005","journal-title":"Nat Rev Immunol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1126\/science.8197455","article-title":"Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins","volume":"264","author":"Darnell","year":"1994","journal-title":"Science"},{"key":"B38","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.ccm.2016.12.012","article-title":"Pulmonary toxicities from checkpoint immunotherapy for malignancy","volume":"38","author":"Possick","year":"2017","journal-title":"Clin Chest Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/nature23270","article-title":"In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target","volume":"547","author":"Manguso","year":"2017","journal-title":"Nature."},{"key":"B40","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1158\/1078-0432.CCR-13-0280","article-title":"Molecular pathways: SWI\/SNF (BAF) complexes are frequently mutated in cancer\u2013mechanisms and potential therapeutic insights","volume":"20","author":"Wang","year":"2014","journal-title":"Clin Cancer Res."},{"key":"B41","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1126\/science.aan5951","article-title":"Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma","volume":"359","author":"Miao","year":"2018","journal-title":"Science."},{"key":"B42","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1126\/science.aao1710","article-title":"A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing","volume":"359","author":"Pan","year":"2018","journal-title":"Science."},{"key":"B43","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/s41586-018-0768-9","article-title":"Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade","volume":"565","author":"Ishizuka","year":"2019","journal-title":"Nature."},{"key":"B44","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/s41586-018-0392-8","article-title":"Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response","volume":"560","author":"Chen","year":"2018","journal-title":"Nature."},{"key":"B45","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s41589-018-0161-x","article-title":"HIP1R targets PD-L1 to lysosomal degradation to alter T cell-mediated cytotoxicity","volume":"15","author":"Wang","year":"2019","journal-title":"Nat Chem Biol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1084\/jem.20180870","article-title":"Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer","volume":"216","author":"Gong","year":"2019","journal-title":"J Exp Med."},{"key":"B47","article-title":"Wnt signaling in cancer","year":""},{"key":"B48","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nature14404","article-title":"Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity","volume":"523","author":"Spranger","year":"2015","journal-title":"Nature."},{"key":"B49","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1038\/sj.onc.1210421","article-title":"MAP kinase signalling pathways in cancer","volume":"26","author":"Dhillon","year":"2007","journal-title":"Oncogene."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1158\/1078-0432.CCR-15-1125","article-title":"RAS\/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: therapeutic cooperation between MEK and PD-1\/PD-L1 immune checkpoint inhibitors","volume":"22","author":"Loi","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B51","doi-asserted-by":"publisher","first-page":"279ra241","DOI":"10.1126\/scitranslmed.aaa4691","article-title":"Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAFV600E melanoma","volume":"7","author":"Hu-Lieskovan","year":"","journal-title":"Science Transl Med"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1158\/1078-0432.CCR-14-2339","article-title":"The BRAF and MEK inhibitors dabrafenib and trametinib: effects on immune function and in combination with immunomodulatory antibodies targeting PD-1, PD-L1, and CTLA-4","volume":"21","author":"Liu","year":"","journal-title":"Clin Cancer Res"},{"key":"B53","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1158\/0008-5472.CAN-15-1938","article-title":"PRC2 epigenetically silences Th1-type chemokines to suppress effector T-cell trafficking in colon cancer","volume":"76","author":"Nagarsheth","year":"2016","journal-title":"Cancer Res."},{"key":"B54","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1158\/2159-8290.CD-15-0283","article-title":"Loss of PTEN promotes resistance to T cell\u2013mediated immunotherapy","volume":"6","author":"Peng","year":"2016","journal-title":"Cancer Discov"},{"key":"B55","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/nm1517","article-title":"Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma","volume":"13","author":"Parsa","year":"2007","journal-title":"Nat Med"},{"key":"B56","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/nature23465","article-title":"CDK4\/6 inhibition triggers anti-tumour immunity","volume":"548","author":"Goel","year":"2017","journal-title":"Nature."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet."},{"key":"B59","doi-asserted-by":"publisher","first-page":"4585","DOI":"10.1158\/1078-0432.CCR-15-3101","article-title":"EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis","volume":"22","author":"Gainor","year":"2016","journal-title":"Clin Cancer Res."},{"key":"B60","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S1470-2045(18)30144-X","article-title":"Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study","volume":"19","author":"Garassino","year":"2018","journal-title":"Lancet Oncol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.3892\/ijo.2016.3632","article-title":"The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6\/JAK\/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer","volume":"49","author":"Zhang","year":"2016","journal-title":"Int J Oncol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1111\/crj.12742","article-title":"Smoking and EGFR status may predict outcomes of advanced NSCLC treated with PD-(L)1 inhibitors beyond first line: a meta-analysis","volume":"12","author":"Abdel-Rahman","year":"2018","journal-title":"Clin Respir J."},{"key":"B63","doi-asserted-by":"publisher","first-page":"10501","DOI":"10.1038\/ncomms10501","article-title":"Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints","volume":"7","author":"Koyama","year":"2016","journal-title":"Nat Commun."},{"key":"B64","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1158\/2159-8290.CD-18-0099","article-title":"STK11\/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma","volume":"8","author":"Skoulidis","year":"2018","journal-title":"Cancer Discov."},{"key":"B65","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/s43018-019-0003-0","article-title":"PAK4 inhibition improves PD-1 blockade immunotherapy","volume":"1","author":"Abril-Rodriguez","year":"2020","journal-title":"Nat Cancer."},{"key":"B66","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.molmed.2016.04.008","article-title":"Learning from PD-1 resistance: new combination strategies","volume":"22","author":"Bu","year":"2016","journal-title":"Trends Mol Med."},{"key":"B67","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13046-015-0221-y","article-title":"Metabolic reprogramming: the emerging concept and associated therapeutic strategies","volume":"34","author":"Yoshida","year":"","journal-title":"J Exp Clin Cancer Res"},{"key":"B68","doi-asserted-by":"publisher","first-page":"417","DOI":"10.3389\/fendo.2019.00417","article-title":"The warburg effect is associated with tumor aggressiveness in testicular germ cell tumors","volume":"10","author":"Bonatelli","year":"2019","journal-title":"Front Endocrinol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.4049\/jimmunol.0902584","article-title":"Lactic acid and acidification inhibit TNF secretion and glycolysis of human monocytes","volume":"184","author":"Dietl","year":"2010","journal-title":"J Immunol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1002\/ijc.25543","article-title":"Warburg phenotype in renal cell carcinoma: high expression of glucose-transporter 1 (GLUT-1) correlates with low CD8+ T-cell infiltration in the tumor","volume":"128","author":"Katrin","year":"2015","journal-title":"Int J Cancer"},{"key":"B71","doi-asserted-by":"publisher","first-page":"5137","DOI":"10.1172\/JCI96268","article-title":"Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy","volume":"128","author":"Jayaprakash","year":"2018","journal-title":"J Clin Invest."},{"key":"B72","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","article-title":"Approaches to treat immune hot, altered and cold tumours with combination immunotherapies","volume":"18","author":"Galon","year":"2019","journal-title":"Nat Rev Drug Discov."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.cell.2015.08.016","article-title":"Metabolic competition in the tumor microenvironment is a driver of cancer progression","volume":"162","author":"Chang","year":"2015","journal-title":"Cell"},{"key":"B74","doi-asserted-by":"publisher","first-page":"5435","DOI":"10.1158\/0008-5472.CAN-12-0569","article-title":"Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion","volume":"72","author":"Platten","year":"2012","journal-title":"Cancer Res."},{"key":"B75","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1080\/13543776.2018.1441290","article-title":"A patent review of IDO1 inhibitors for cancer","volume":"28","author":"Cheong","year":"2018","journal-title":"Expert Opin Ther Patents."},{"key":"B76","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1084\/jem.20130066","article-title":"Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4","volume":"210","author":"Holmgaard","year":"2013","journal-title":"J Exp Med."},{"key":"B77","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/nrm2336","article-title":"Cellular cholesterol trafficking and compartmentalization","volume":"9","author":"Ikonen","year":"2008","journal-title":"Nat Rev Mol Cell Biol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.tips.2012.03.013","article-title":"Liver X receptor biology and pharmacology: new pathways, challenges and opportunities","volume":"33","author":"Jakobsson","year":"2012","journal-title":"Trends Pharmacol Sci"},{"key":"B79","doi-asserted-by":"publisher","first-page":"6378","DOI":"10.1038\/onc.2016.168","article-title":"Abrogating cholesterol esterification suppresses growth and metastasis of pancreatic cancer","volume":"35","author":"Li","year":"2016","journal-title":"Oncogene."},{"key":"B80","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/nature17412","article-title":"Potentiating the antitumour response of CD8+ T cells by modulating cholesterol metabolism","volume":"531","author":"Yang","year":"2016","journal-title":"Nature."},{"key":"B81","doi-asserted-by":"publisher","first-page":"932","DOI":"10.4049\/jimmunol.173.2.932","article-title":"Adenosine acts through A2 receptors to inhibit IL-2-induced tyrosine phosphorylation of STAT5 in T lymphocytes: role of cyclic adenosine 3',5'-monophosphate and phosphatases","volume":"173","author":"Zhang","year":"2004","journal-title":"J Immunol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"4372","DOI":"10.1158\/0008-5472.CAN-16-0544","article-title":"Adenosine 2B receptor expression on cancer cells promotes metastasis","volume":"76","author":"Mittal","year":"2016","journal-title":"Cancer Res."},{"key":"B83","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1073\/pnas.0908801107","article-title":"Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis","volume":"107","author":"Stagg","year":"2010","journal-title":"Proc Natl Acad Sci USA."},{"key":"B84","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1002\/ijc.28456","article-title":"Anti-CD73 therapy impairs tumor angiogenesis","volume":"134","author":"Allard","year":"2014","journal-title":"Int J Cancer."},{"key":"B85","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1158\/1078-0432.CCR-15-1181","article-title":"CD73 expression is an independent prognostic factor in prostate cancer","volume":"22","author":"Leclerc","year":"2016","journal-title":"Clin Cancer Res."},{"key":"B86","doi-asserted-by":"publisher","first-page":"e1046675","DOI":"10.1080\/2162402X.2015.1046675","article-title":"CD73: A potential biomarker for anti-PD-1 therapy","volume":"4","author":"Beavis","year":"2015","journal-title":"Oncoimmunology."},{"key":"B87","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/nri2580","article-title":"New insights into the regulation of T cells by \u03b3 c family cytokines","volume":"9","author":"Rochman","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.immuni.2009.04.010","article-title":"Mechanisms of Foxp3+ T regulatory cell-mediated suppression","volume":"30","author":"Shevach","year":"","journal-title":"Immunity"},{"key":"B89","doi-asserted-by":"publisher","first-page":"3356","DOI":"10.1172\/JCI80005","article-title":"Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected","volume":"125","author":"Marvel","year":"2015","journal-title":"J Clin Invest."},{"key":"B90","doi-asserted-by":"publisher","first-page":"3365","DOI":"10.1172\/JCI80006","article-title":"Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages","volume":"125","author":"Ugel","year":"2015","journal-title":"J Clin Invest."},{"key":"B91","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/2326-6066.CIR-16-0297","article-title":"Myeloid-derived suppressor cells","volume":"5","author":"Gabrilovich","year":"2017","journal-title":"Cancer Immunol Res."},{"key":"B92","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1146\/annurev-med-051013-052304","article-title":"Regulation of tumor metastasis by myeloid-derived suppressor cells","volume":"66","author":"Condamine","year":"2015","journal-title":"Annu Rev Med."},{"key":"B93","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.it.2010.10.002","article-title":"Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function","volume":"32","author":"Condamine","year":"2011","journal-title":"Trends Immunol."},{"key":"B94","doi-asserted-by":"publisher","first-page":"55804","DOI":"10.18632\/oncotarget.18437","article-title":"Resistance to CTLA-4 checkpoint inhibition reversed through selective elimination of granulocytic myeloid cells","volume":"8","author":"Clavijo","year":"2017","journal-title":"Oncotarget."},{"key":"B95","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cytogfr.2009.11.007","article-title":"The chemokine system in cancer biology and therapy","volume":"21","author":"Mantovani","year":"2010","journal-title":"Cytokine Growth Factor Rev"},{"key":"B96","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/nature07205","article-title":"Cancer-related inflammation","volume":"454","author":"Mantovani","year":"","journal-title":"Nature"},{"key":"B97","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.cell.2010.03.015","article-title":"Matrix metalloproteinases: regulators of the tumor microenvironment","volume":"141","author":"Kai","year":"2010","journal-title":"Cell"},{"key":"B98","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.immuni.2014.06.010","article-title":"Tumor-associated macrophages: from mechanisms to therapy","volume":"41","author":"Noy","year":"2014","journal-title":"Immunity"},{"key":"B99","doi-asserted-by":"publisher","first-page":"eaa13604","DOI":"10.1126\/scitranslmed.aal3604","article-title":"In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy","volume":"9","author":"Arlauckas","year":"2017","journal-title":"Sci Transl Med"},{"key":"B100","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/nature10673","article-title":"Cancer immunotherapy comes of age","volume":"480","author":"Mellman","year":"2011","journal-title":"Nature."},{"key":"B101","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1158\/2326-6066.CIR-15-0097","article-title":"Progression of lung cancer is associated with increased dysfunction of T cells defined by coexpression of multiple inhibitory receptors","volume":"3","author":"Thommen","year":"2015","journal-title":"Cancer Immunol Res."},{"key":"B102","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1126\/science.aaf0683","article-title":"Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent","volume":"355","author":"Kamphorst","year":"2017","journal-title":"Science"},{"key":"B103","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/35025220","article-title":"Angiogenesis in cancer and other diseases","volume":"407","author":"Carmeliet","year":"2000","journal-title":"Nature."},{"key":"B104","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/nri.2017.145","article-title":"Improving immune-vascular crosstalk for cancer immunotherapy","volume":"18","author":"Huang","year":"2018","journal-title":"Nat Rev Immunol."},{"key":"B105","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nri3175","article-title":"Coordinated regulation of myeloid cells by tumours","volume":"12","author":"Gabrilovich","year":"2012","journal-title":"Nat Rev Immunol."},{"key":"B106","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/imm.12380","article-title":"Hypoxia-inducible factors in regulation of immune responses in tumour microenvironment","volume":"143","author":"Kumar","year":"2014","journal-title":"Immunology."},{"key":"B107","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1158\/0008-5472.CAN-13-0992","article-title":"A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells","volume":"74","author":"Barsoum","year":"2014","journal-title":"Cancer Res."},{"key":"B108","first-page":"537","article-title":"Aging, immunity, and cancer","volume":"11","author":"Fulop","year":"2011","journal-title":"Discov Med."},{"key":"B109","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ctrv.2016.02.006","article-title":"Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: a systematic review and meta-analysis","volume":"45","author":"Nishijima","year":"2016","journal-title":"Cancer Treat Rev."},{"key":"B110","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/S1470-2045(18)30261-4","article-title":"Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis","volume":"19","author":"Conforti","year":"2018","journal-title":"Lancet Oncol."},{"key":"B111","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1001\/jama.2019.0463","article-title":"The surprisingly positive association between obesity and cancer immunotherapy efficacy","volume":"321","author":"Murphy","year":"2019","journal-title":"JAMA."},{"key":"B112","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.immuni.2016.06.001","article-title":"Resistance mechanisms to immune-checkpoint blockade in cancer: tumor-intrinsic and -extrinsic factors","volume":"44","author":"Pitt","year":"2016","journal-title":"Immunity."},{"key":"B113","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1126\/science.aac4255","article-title":"Commensal bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy","volume":"350","author":"Sivan","year":"2015","journal-title":"Science."},{"key":"B114","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1126\/science.aad1329","article-title":"Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota","volume":"350","author":"V\u00e9tizou","year":"2015","journal-title":"Science."}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.01290\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T10:33:11Z","timestamp":1597314791000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.01290\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,6]]},"references-count":114,"alternative-id":["10.3389\/fonc.2020.01290"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2020.01290","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,6]]},"article-number":"1290"}}